Trials
Search / Trial NCT06418763

The Effects of Fermented Brown Seaweed Intake on Glucose Metabolism and Gut Health

Launched by AVENTURE AB · May 16, 2024

Trial Information

Current as of February 19, 2025

Active, not recruiting

Keywords

Seaweed Blood Glucose Gut Microbiota

ClinConnect Summary

Fermented seaweed is a sustainable food with increasing interest as an ingredient of a plant-based diet. Plant-based diets are gaining popularity both because of their health benefits and low-carbon footprint. Seaweed is a rich source of minerals, polyphenols and dietary fibres like xylans, carrageenan, fucoidan, laminarin and alginate. These bioactive compounds have been shown to exert positive effects on metabolic parameters, such as blood glucose and insulin, blood lipid profile and inflammatory markers and could therefore help in the prevention of cardiovascular diseases. Besides possib...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Healthy males and females
  • Age 20-40 years, at the time of signing the informed consent
  • BMI 20-25 kg/m2
  • Stable body weight (less than 5% difference during the last 3 months)
  • Willing and able to give written informed consent for participating the study
  • Willing to comply with all study procedures
  • Exclusion Criteria:
  • Intake of antibiotics within 4 weeks prior to the start of the study
  • Regular intake of probiotics and/or prebiotics within 4 weeks prior to the start of the study
  • Tobacco use (smoking and/or snus)
  • High alcohol intake: \> 4 glasses daily
  • Pregnancy or lactating
  • Chronical disease (e.g., liver, kidney)
  • Diabetes
  • Gastrointestinal disease (ulcerative colitis, Crohn's disease, irritable bowel syndrome)
  • Heart disease (within the last 12 months)
  • Inflammatory disease (e.g. asthma, GI inflammatory diseases) and auto-immune disease
  • Treatment with corticosteroids of significant degree
  • Psychological disease of significant degree
  • Cancer of significant difference
  • Gastric-bypass operation
  • Operation planned during the study period
  • Known gluten intolerance and/or lactose intolerance
  • Having allergies to the food components of the study, mustard and seafoods
  • Known gluten intolerance, lactose intolerance, milk protein allergy or other food allergies
  • Irregular diet (i.e., not eating 3 main meals daily) or special diet (e.g. vegan, low-carb high-fat, 5-2)
  • Investigator considers the subject unlikely to comply with the study procedures, restrictions, and requirements

Trial Officials

Lieselotte Cloetens

Principal Investigator

Lund University

About Aventure Ab

Aventure AB is a biopharmaceutical company dedicated to advancing innovative therapies aimed at addressing unmet medical needs in various therapeutic areas. With a strong focus on research and development, Aventure AB collaborates with leading academic institutions and industry partners to drive clinical trials and accelerate the translation of scientific discoveries into effective treatments. Committed to improving patient outcomes, the company emphasizes rigorous clinical practices, ethical standards, and a patient-centric approach in all its initiatives. Through its strategic vision and commitment to excellence, Aventure AB strives to be at the forefront of medical innovation.

Locations

Lund, , Sweden

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0